Genmab — Juni 2025
-
https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.
-
Investigational combination of first-in-class bispecifics TALVEY
and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html -
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL https://www.onclive.com/view/fixed-duration-epcoritamab-plus-pola-r-chp-demonstrates-durable-efficacy-in-first-line-dlbcl
-
Genmab har lovende resultater med kræftmiddel i lymfekræftform https://proinvestor.com/investornyt/1329375/genmab-har-lovende-resultater-med-kraeftmiddel-i-lymfekraeftform
-
Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1329527/transactions-in-connection-with-share-buy-back-program
-
EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial https://finance.yahoo.com/news/eha-2025-genmab-abbvie-epkinly-134631049.html
-
Hej wisuwa...Du kan evt starte med at læse chathistorikken.
https://proinvestor.com/chathistory/-25/genmab -
Jyske Bank: Genmab – Positivt nyt fra Epcoritamab https://proinvestor.com/investornyt/1329914/jyske-bank-genmab-positivt-nyt-fra-epcoritamab
-
España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes https://www.immedicohospitalario.es/noticia/51673/espana-lidera-un-estudio-pionero-con-epcoritamab-para-mejorar-el-abor.html REPIFIR = Response-adaptive to Epcoritamab In FIrst Relapse
-
Presentations & posters for EHA 2025 via https://www.genmabmedicalaffairs.com/congress?filv1=5
-
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy. https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge -
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant
-
EHA 2025 | How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are ASCT eligible? https://www.youtube.com/watch?v=bCdPlWOjJ1M
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind